Skip to main content
Top

Clinical and Translational Oncology

Issue 10/2005

Content (9 Articles)

Editorial

Clinical trials: Bad combinations or bad designs

Juan de la Haba-Rodríguez, Auxiliadora Gómez, Enrique Aranda

Review

Cytoreductive surgery and intraoperative intraperitoneal hyperthermic chemotherapy in patients with peritoneal carcinomatosis of colorectal origin

César P. Ramírez Plaza, Manuel A. Cobo Dols, Alberto Gómez Portilla, Agustín de la Fuente Perucho

Original Articles

Interdisciplinary clinical evaluation of 58 patients with lumbar-vertebral metastases from cervico-uterine cancer

Víctor Valdespino Gómez, Juan M. Salgado Cazares, Gaspar González Astudillo, Víctor E. Valdespino Castillo

Original Articles

Efectividad de 5-fluoruracilo y vinorelbina en pacientes multitratadas por cáncer de mama metastásico

José Luis González Vela, Jorge Martín Sánchez Guillén, Sergio Arnoldo Treviño Aguirre, David Hernández Barajas, William Orlando Brito Villanueva, Eloy Cárdenas Estrada, Juan Francisco González Guerrero

Original Articles

Radioterapia estereotáxica fraccionada en adenomas de hipófisis: resultados y factores pronósticos

Rosa M Cañón Rodríguez, David Ortiz de Urbina, Juan Carlos Viera, César Beltrán, Fernando Puebla, M Isabel García Berrocal, Ana Mañas, Carmen Peraza, Felipe A. Calvo

Case Reports

Metástasis en mama

Dolores Arribas del Amo, M. Pilar Santero Ramírez, Elena Córdoba Díaz de Laspra, Fernando Martínez Ubieto, Mónica Corral Subías, Alfonso Cay Diarte

Case Reports

Gastrointestinal bleeding as the first manifestation of a burned-out tumour of the testis

Cecilia Castillo, Gabriel Krygier, Julio Carzoglio, Raúl Cepellini Magariños, Raúl Cepellini Olmos, Juan Jubín, Graciela Sabini

Case Reports

Lumbar region intra-spinal primitive neuroectodermal tumour (PNET) combined with neurofibromatosis type 1

Uriel Bohn Sarmiento, David Aguiar Bujanda, Rafael Camacho Galán, José C. Rivero Vera, José Aguiar Morales

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine